Health ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Monoclonal Antibodies FDA Approval Obesity Treatments Lenacapavir Efficacy Studies Semaglutide Phase 3 Trials Efzofitimod Regulatory Approval Innovative Treatments Regulatory Affairs Market Claims Simufilam Weight Loss Drugs Novo Nordisk Pfizer Rare Diseases GLP-1 Drugs Innovative Therapies Retatrutide Investigational Drugs Multiple Sclerosis Antivenom Production Weight-loss Medicines Phase II Trials Baxdrostat FDA-Approved Drugs Human Trials Patient Outcomes AI in Healthcare AbbVie Research and Development Hypertension Treatments Data Protection Safety and Efficacy Obesity Treatment Olezarsen Lipid-Lowering Drugs Investor Impact FDA Approvals Tolebrutinib GLP-1 Receptor Agonists Biontech Regulatory Changes Drug Effectiveness Market Competition New Medications COVID-19 Vaccines Cancer Treatment UK Healthcare System Diabetes Treatments Autoimmune Disorders Chronic Hepatitis B Feline Medications Therapeutics Methylenomicina A Next-Generation Treatments PCSK9 Inhibitors Ganaplacide-Lumefantrine Breast Cancer Treatments Efficacy Claims Nimacimab Antibiotics Alzheimer's Disease Wegovy Type 2 Diabetes Schizophrenia Biologics Efficacy and Safety Zoliflodacin Psoriasis Treatment Osteogenesis Imperfecta Prostate Cancer Experimental Treatments Preclinical Studies Product Efficacy Motion Sickness Social Anxiety Disorder Immunology Therapeutic Candidates Setrusumab Male Contraceptive Trials Huntington's Disease Long-acting Injectables Nanobodies Molecular Therapy Postpartum Depression Mental Health Gastroparesis Growth Hormone Deficiency Drug Behavior Prediction Drug Simulation Virtual Testing ITI-1284 Sodium Channel Blockers Safety Concerns Obeldesivir Cancer Treatments Weight Loss AI in Drug Design

NCI Pursues Preclinical Test of Ivermectin’s Anti-Cancer Activity

The move, disclosed by director Anthony Letai, has drawn internal alarm over spending on a drug with no credible clinical benefit.

Lilly and Innovent Forge Territory-Split Cancer and Immunology Alliance

Vistagen Hit With Securities Class Actions After Phase 3 Miss as Investors Face March 16 Deadline

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Skye Bioscience Investors Face Friday Deadline in Securities Class Action Over Nimacimab Disclosures

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

FDA Issues Complete Response Letter for Corcept’s Relacorilant in Cushing’s-Related Hypertension

Law Firms Urge Telix Investors as Jan. 9 Lead-Plaintiff Deadline Nears

Skye Bioscience Faces Investor Class Actions as Firms Court Shareholders Before Jan. 16 Deadline

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

FDA Clears First New Oral Gonorrhea Antibiotics in Over 30 Years

Chai Discovery Raises $130 Million Series B at $1.3 Billion Valuation

MoonLake Immunotherapeutics Investors Face Lead‑Plaintiff Deadline in Securities Fraud Suits

First GLP‑1 Implant Trial for Obese Cats Begins With First Patient Dosed

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

MoonLake Faces Expanding Securities Suits as Lead-Plaintiff Deadline Nears

aTyr Pharma Lead‑Plaintiff Deadline Hits as Rival Firms Vie to Steer Securities Case

aTyr Investors Face Dec. 8 Deadline in Securities Suits Over Efzofitimod Trial Failure